• 1
    Hammond, M. E., D. F. Hayes, M. Dowsett, D. C. Allred, K. L. Hagerty, S. Badve, et al. 2010. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28:27842795.
  • 2
    Burstein, H. J., A. A. Prestrud, J. Seidenfeld, H. Anderson, T. A. Buchholz, N. E. Davidson, et al. 2010. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28:37843796.
  • 3
    Dowsett, M., C. Allred, J. Knox, E. Quinn, J. Salter, C. Wale, et al. 2008. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J. Clin. Oncol. 26:10591065.
  • 4
    Yerushalmi, R., R. Woods, P. M. Ravdin, M. M. Hayes, and K. A. Gelmon. 2010. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11:174183.
  • 5
    Badve, S., D. Turbin, M. A. Thorat, A. Morimiya, T. O. Nielsen, C. M. Perou, et al. 2007. FOXA1 expression in breast cancer – correlation with luminal subtype A and survival. Clin. Cancer Res. 13:44154421.
  • 6
    Kouros-Mehr, H., E. M. Slorach, M. D. Sternlicht, and Z. Werb. 2006. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127:10411055.
  • 7
    Albergaria, A., J. Paredes, B. Sousa, F. Milanezi, V. Carneiro, J. Bastos, et al. 2009. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res. 11:R40.
  • 8
    Pujol, P., J. P. Daures, S. Thezenas, F. Guilleux, P. Rouanet, and J. Grenier. 1998. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 83:698705.
  • 9
    Rutanen, E. M., F. Pekonen, T. Nyman, and T. Wahlström. 1993. Insulin-like growth factors and their binding proteins in benign and malignant uterine diseases. Growth Regul. 3:7477.
  • 10
    O'Toole, S. A., E. Dunn, B. L. Sheppard, O. Sheils, J. J. O'Leary, W. Wuttke, et al. 2005. Oestrogen regulated gene expression in normal and malignant endometrial tissue. Maturitas 51:187198.
  • 11
    Hayashi, S. I., H. Eguchi, K. Tanimoto, T. Yoshida, Y. Omoto, A. Inoue, et al. 2003. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr. Relat. Cancer 10:193202.
  • 12
    Hayashi, S., T. Niwa, and Y. Yamaguchi. 2009. Estrogen signaling pathway and its imaging in human breast cancer. Cancer Sci. 100:17731778.
  • 13
    Campbell, R. A., P. Bhat-Nakshatri, N. M. Patel, D. Constantinidou, S. Ali, and H. Nakshatri. 2001. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 276:98179824.
  • 14
    Stoica, G. E., T. F. Franke, M. Moroni, S. Mueller, E. Morgan, M. C. Iann, et al. 2003. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 22:79988011.
  • 15
    Inoue, A., N. Yoshida, Y. Omoto, S. Oguchi, T. Yamori, R. Kiyama, et al. 2002. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J. Mol. Endocrinol. 29:175192.
  • 16
    Inoue, A., Y. Omoto, Y. Yamaguchi, R. Kiyama, and S. I. Hayashi. 2004. Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. J. Mol. Endocrinol. 32:649661.
  • 17
    Yoshida, N., Y. Omoto, A. Inoue, H. Eguchi, Y. Kobayashi, M. Kurosumi, et al. 2004. Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci. 95:496502.
  • 18
    Matsumoto, M., H. Sakamoto, Y. Yamaguchi, Y. Seino, H. Takei, M. Kurosumi, et al. 2009. 3-Dimensional microarray analysis of estrogen signal-related genes in breast cancer tissues. Anticancer Res. 29:39713975.
  • 19
    Omoto, Y., Y. Kobayashi, K. Nishida, E. Tsuchiya, H. Eguchi, K. Nakagawa, et al. 2001. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem. Biophys. Res. Commun. 285:340347.
  • 20
    Matsumoto, M., Y. Yamaguchi, Y. Seino, A. Hatakeyama, H. Takei, H. Niikura, et al. 2008. Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction. Endocr. Relat. Cancer 15:451463.
  • 21
    Kurosumi, M. 2003. Significance of immunohistochemical assessment of steroid hormone receptor status for breast cancer patients. Breast Cancer 10:97104.
  • 22
    Allred, D. C., J. M. Harvey, M. Berardo, and G. M. Clark. 1998. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 11:155168.
  • 23
    Elston, C. W., and I. O. Ellis. 1991. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403410.
  • 24
    Ackerman, G. E., M. E. Smith, C. R. Mendelson, P. C. MacDonald, and E. R. Simpson. 1981. Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J. Clin. Endocrinol. Metab. 53:412417.
  • 25
    Tokuda, E., Y. Seino, A. Arakawa, M. Saito, F. Kasumi, S. I. Hayashi, et al. 2012. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer. Breast Cancer Res. Treat. 133:427436.
  • 26
    Yamaguchi, Y., H. Takei, K. Suemasu, Y. Kobayashi, M. Kurosumi, N. Harada, et al. 2005. Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer. Cancer Res. 65:46534662.
  • 27
    Gauduchon, J., F. Gouilleux, S. Maillard, V. Marsaud, J. M. Renoir, and B. Sola. 2005. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members. Clin. Cancer Res. 11:23452354.
  • 28
    Safe, S., and K. Kim. 2004. Nuclear receptor-mediated transactivation through interaction with Sp proteins. Prog. Nucleic Acid Res. Mol. Biol. 77:136.
  • 29
    Hewitt, S. C., and K. S. Korach. 2002. Estrogen receptors: structure, mechanisms and function. Rev. Endocr. Metab. Disord. 3:193200.